Eisai Co., Ltd. (ESALF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Haruo Naito.
ESALF hat IPO-Datum 2011-04-07, 11,067 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $8.46B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that develops and markets a diverse portfolio of prescription and over-the-counter products across multiple therapeutic areas. The company's key branded medications include Aricept for Alzheimer's disease and Lewy body dementia, Fycompa for epilepsy, Dayvigo for insomnia, and Lenvima for various cancers including thyroid, renal cell, and hepatocellular carcinoma. Eisai also markets Halaven for breast cancer and liposarcoma, Lyrica for pain management, Pariet for gastrointestinal disorders, and Humira for autoimmune diseases, alongside consumer health products such as vitamin supplements and designated quasi-drugs. The company serves the Japanese market as a leading player in both prescription pharmaceuticals and consumer health categories.
